BioPharmSignal logoBioPharmSignal

Biotech News

Axsome Therapeutics to Participate in Upcoming Investor Conferences

Axsome (AXSM)AxsomeCompany update

Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that it will participate in the following upcoming investor conferences in November:

Related news

AXSMAxsome2026-10-07 11:00 EST

Axsome Therapeutics to Report Third Quarter 2026 Financial Results on November 2

AXSMAxsome2026-09-17 11:00 EST

Axsome Therapeutics Presents Ten Posters Exemplifying its Innovative Psychiatry and Neurology Portfolio at Psych Congress 2026

IKTInhibikase Therapeutics2026-10-27 12:00 EST

Inhibikase Therapeutics Announces Participation in Upcoming Investor Conferences During November 2026

ABOSAcumen Pharmaceuticals2026-09-02 20:00 EST

Acumen Pharmaceuticals to Participate in Upcoming Investor Conferences

ANNXAnnexon, Inc.2026-09-02 12:00 EST

Annexon to Participate in Upcoming September Investor Conferences

NERVMinerva Neuroscience2026-08-28 12:00 EST

Minerva Neurosciences to Participate in Two Upcoming Investor Conferences

GANXGain Therapeutics2026-11-05 12:00 EST

Gain Therapeutics Announces Late-Breakers and Poster Presentations at Upcoming Scientific Conferences

MNOVMediciNova2026-09-08 10:00 EST

MediciNova to Participate in Two Investor Conferences in September

KTTAPasithea Therapeutics2026-09-03 20:05 EST

Pasithea Therapeutics Announces Participation in Two September 2026 Investor Conferences

SUPNSupernus2026-09-02 20:30 EST

Supernus Pharmaceuticals to Participate in September Investor Conferences

View all latest news

Axsome

CNS Commercial Portfolio Axsome Therapeutics develops and commercializes medicines for central nervous system disorders. Its business combines marketed products in depression, migraine and sleep disorders with a pipeline spanning psychiatry and neurology. AUVELITY AUVELITY is an oral NMDA receptor antagonist and sigma-1 receptor agonist...

Recent company news

AXSMAxsome2026-11-03 12:00 EST

Axsome Therapeutics to Participate in Upcoming Investor Conferences

AXSMAxsome2026-10-07 11:00 EST

Axsome Therapeutics to Report Third Quarter 2026 Financial Results on November 2

AXSMAxsome2026-09-21 11:00 EST

Axsome Therapeutics Announces Results of the Shared Goals Survey of Caregivers of Patients with Alzheimer’s Disease Agitation Presented at Psych Congress 2026 in Connection with World Alzheimer’s Day

AXSMAxsome2026-09-17 11:00 EST

Axsome Therapeutics Presents Ten Posters Exemplifying its Innovative Psychiatry and Neurology Portfolio at Psych Congress 2026

AXSMAxsome2026-09-02 11:00 EST

Axsome Therapeutics to Participate in Upcoming Investor Conferences

Stock data

Close
129.80 USD
Market cap
11.43B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States